Reported Earnings • Aug 16
Second quarter 2026 earnings released: EPS: kr0.10 (vs kr0.06 in 2Q 2025) Second quarter 2026 results: EPS: kr0.10 (up from kr0.06 in 2Q 2025). Revenue: kr33.9m (up 17% from 2Q 2025). Net income: kr5.25m (up 60% from 2Q 2025). Profit margin: 16% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.6% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • May 09
First quarter 2026 earnings released: EPS: kr0.01 (vs kr0.06 loss in 1Q 2025) First quarter 2026 results: EPS: kr0.01 (up from kr0.06 loss in 1Q 2025). Revenue: kr35.0m (up 41% from 1Q 2025). Net income: kr585.0k (up kr3.69m from 1Q 2025). Profit margin: 1.7% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Ankündigung • May 02
Arcticzymes Technologies Asa Strengthens Ip Platform with New Patent Grant Supporting Expansion into Rna Therapeutics Manufacturing ArcticZymes Technologies ASA announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company's strategic expansion into the rapidly growing RNA therapeutics manufacturing market. The newly granted patent strengthens ArcticZymes' proprietary technology platform with the introduction of a novel RNA restriction enzyme family focused on enabling analytical, process development and manufacturing workflows for therapeutic RNA production. The protection covers key application areas relevant to RNA processing, quality control and scalable manufacturing workflows. The global RNA therapeutics market continues to expand, driven by increasing clinical activity in mRNA, self-amplifying RNA, circular RNA and other novel modalities. As programmes progress toward late-stage development and commercialisation, demand is rising for robust, scalable and IP-secure manufacturing technologies that can improve process efficiency, product quality and regulatory confidence. ArcticZymes expects the protected technology to strengthen ongoing business development discussions with prospective partners and customers active in RNA therapeutics manufacturing. ArcticZymes will continue investing in internal innovation, targeted IP creation and strategic collaborations to expand its presence in high-growth biomanufacturing segments. ArcticZymes believes RNA therapeutics represents a significant long-term growth opportunity and remains committed to building a differentiated portfolio of enabling technologies to serve this expanding market. New Risk • Mar 27
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: kr970.4m (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Market cap is less than US$100m (kr970.4m market cap, or US$99.6m). Board Change • Mar 10
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Employee Elected Observer Lill-Hege Henriksen is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Feb 15
Full year 2025 earnings released: EPS: kr0.19 (vs kr0.17 in FY 2024) Full year 2025 results: EPS: kr0.19 (up from kr0.17 in FY 2024). Revenue: kr118.2m (up 9.3% from FY 2024). Net income: kr9.88m (up 17% from FY 2024). Profit margin: 8.4% (up from 7.8% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.1% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. New Risk • Jan 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Board Change • Jan 07
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Employee Elected Observer Lill-Hege Henriksen is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Ankündigung • Dec 20
ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026 ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026. New Risk • Dec 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: kr970.4m (US$96.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (kr970.4m market cap, or US$96.0m). Reported Earnings • Nov 07
Third quarter 2025 earnings released: EPS: kr0.06 (vs kr0.03 loss in 3Q 2024) Third quarter 2025 results: EPS: kr0.06 (up from kr0.03 loss in 3Q 2024). Revenue: kr29.8m (up 23% from 3Q 2024). Net income: kr3.30m (up kr4.86m from 3Q 2024). Profit margin: 11% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Aug 19
Director recently bought kr68k worth of stock On the 14th of August, Sharon Brownlow bought around 3k shares on-market at roughly kr24.00 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr433k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: kr0.06 (vs kr0.05 in 2Q 2024) Second quarter 2025 results: EPS: kr0.06 (up from kr0.05 in 2Q 2024). Revenue: kr28.9m (up 4.9% from 2Q 2024). Net income: kr3.28m (up 23% from 2Q 2024). Profit margin: 11% (up from 9.7% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Jun 08
Vice President of Operations recently bought kr54k worth of stock On the 3rd of June, Marit Lorentzen bought around 3k shares on-market at roughly kr16.00 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Marit has been a buyer over the last 12 months, purchasing a net total of kr124k worth in shares. Reported Earnings • May 09
First quarter 2025 earnings released: kr0.06 loss per share (vs kr0.06 profit in 1Q 2024) First quarter 2025 results: kr0.06 loss per share (down from kr0.06 profit in 1Q 2024). Revenue: kr24.9m (down 17% from 1Q 2024). Net loss: kr3.11m (down 198% from profit in 1Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 32 percentage points per year, which is a significant difference in performance. Board Change • Apr 30
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Employee Elected Observer Lill-Hege Henriksen is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. New Risk • Feb 16
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (22% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (7.0% net profit margin). Market cap is less than US$100m (kr970.4m market cap, or US$87.3m). Reported Earnings • Feb 14
Full year 2024 earnings released: EPS: kr0.15 (vs kr0.38 in FY 2023) Full year 2024 results: EPS: kr0.15 (down from kr0.38 in FY 2023). Revenue: kr108.1m (down 9.6% from FY 2023). Net income: kr7.57m (down 61% from FY 2023). Profit margin: 7.0% (down from 16% in FY 2023). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 43% per year, which means it has not declined as severely as earnings. Ankündigung • Dec 09
ArcticZymes Technologies ASA Expands San HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers ArcticZymes Technologies introduced two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector. The new SAN HQ ELISA Senso Plus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as a reusable format, reduced assay execution times, and lower costs make it an invaluable tool for streamlining biomanufacturing operations. Complementing SensoPlus, the new SAN HQ GMP neo delivers a GMP-compliant version of ArcticZymes' widely utilized SAN HQ Triton FREE. This product reflects ArcticZymes' commitment to expanding its portfolio of high-performance nucleases, providing biomanufacturers the flexibility to select solutions tailored to their unique production needs. By adding GMP variants to its portfolio, ArcticZymes is proactively addressing the increasingly stringent regulatory requirements of the biomanufacturing industry, enabling partners to achieve compliance with global standards while optimizing their production processes. Ankündigung • Dec 04
ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025 ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025. Recent Insider Transactions • Nov 10
Chief Executive Officer recently bought kr102k worth of stock On the 7th of November, Michael Akoh bought around 8k shares on-market at roughly kr13.26 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months. New Risk • Nov 07
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.3% Last year net profit margin: 15% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (6.3% net profit margin). Market cap is less than US$100m (kr704.8m market cap, or US$64.4m). Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to kr14.72, the stock trades at a forward P/E ratio of 32x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to kr17.32, the stock trades at a forward P/E ratio of 34x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total loss to shareholders of 80% over the past three years. New Risk • Aug 26
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (22% accrual ratio). Reported Earnings • Aug 23
Second quarter 2024 earnings released: EPS: kr0.05 (vs kr0.11 in 2Q 2023) Second quarter 2024 results: EPS: kr0.05 (down from kr0.11 in 2Q 2023). Revenue: kr27.5m (down 2.4% from 2Q 2023). Net income: kr2.67m (down 52% from 2Q 2023). Profit margin: 9.7% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to kr26.15, the stock trades at a forward P/E ratio of 48x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr50.39 per share. Ankündigung • Jul 31
ArcticZymes Technologies ASA Announces the Appointment of Frank Mathias as Chairman of the Board of Directors Oxford Biomedica plc announced that Dr. Frank Mathias, Chief Executive Officer, has been appointed as Chairman of the Board of Directors of ArcticZymes Technologies ASA. New Risk • May 17
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 28% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (28% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (16% net profit margin). Board Change • May 15
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jane Theaker was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • May 14
ArcticZymes Technologies ASA Announces Board Resignations ArcticZymes Technologies ASA announced changes to its governance structure. The Election committee has proposed changes to the Board to guide and strengthen the strategic and commercial development of the company. Mrs. Marie Roskrow, Chairman of the Board, has resigned, effective immediately. During her six-year tenure, Mrs. Roskrow played a pivotal role in elevating ArcticZymes into a globally profitable player in the life science tools sector. Her leadership laid a robust foundation for long-term growth, for which the Election committee extends its sincere appreciation. Board member Mrs. Jane Theaker has also resigned, citing personal reasons. The committee acknowledges Mrs. Theaker's valuable contributions and thanks her for her service. Ankündigung • Apr 02
ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board Member ArcticZymes Technologies ASA announced Board member Edgar Koster has informed the board that he will resign from the board with immediate effect for personal reasons. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to kr29.15, the stock trades at a forward P/E ratio of 70x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 60% over the past three years. New Risk • Feb 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (16% net profit margin). New Risk • Feb 07
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (16% net profit margin). Reported Earnings • Feb 02
Full year 2023 earnings released: EPS: kr0.37 (vs kr0.65 in FY 2022) Full year 2023 results: EPS: kr0.37 (down from kr0.65 in FY 2022). Revenue: kr119.7m (down 13% from FY 2022). Net income: kr18.7m (down 43% from FY 2022). Profit margin: 16% (down from 24% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Ankündigung • Jan 30
Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San Hq ArcticZymes Technologies ASA announced the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). SAN HQ GMP from ArcticZymes offers a technically superior solution for the enzymatic removal of contaminating DNA from therapeutic products such as viral vectors and vaccines. With the new SAN HQ GMP, ArcticZymes extends its portfolio to include a GMP-grade nuclease. ArcticZymes recognizes the challenges faced by bio-manufacturers in the advanced therapies sector. To streamline the supplier and material qualification process and to enhance compliance for pharmaceutical industry clients, SAN HQ GMP serves as a superior solution. The inclusion of a US FDA DMF further facilitates regulatory submission. SAN HQ GMP not only offers a technically superior option for enzymatic applications and provides a more straightforward supplier qualification process for customers. By reducing risks and minimizing resource expenditure on external product qualification, the new SAN HQ GMP ensures that clients in the pharmaceutical industry can access the most cutting-edge solution without compromising on compliance. The new SAN HQ GMP will be available for ordering in the second half of February 2024. Ankündigung • Dec 21
ArcticZymes Technologies ASA Launches T7 RNA Polymerase ArcticZymes Technologies ASA announced the launch of its new product, T7 RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA Polymerase is intended for use in molecular research and diagnostics. The enzyme precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled for 2024. The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting synergies between its business segments. While the field of RNA therapeutics is rapidly evolving, the T7 RNA Polymerase may support different research areas as well as being a key component in various molecular diagnostic applications. The T7 RNA Polymerase will be available for ordering during January 2024. New Risk • Nov 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (15% net profit margin). Reported Earnings • Nov 03
Third quarter 2023 earnings released: EPS: kr0.12 (vs kr0.05 in 3Q 2022) Third quarter 2023 results: EPS: kr0.12 (up from kr0.05 in 3Q 2022). Revenue: kr31.2m (up 4.9% from 3Q 2022). Net income: kr6.06m (up 143% from 3Q 2022). Profit margin: 20% (up from 8.4% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Ankündigung • Sep 21
ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA ArcticZymes Technologies ASA announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has passed the DMF filing Type II with the US Food and Drug Administration (FDA) and has received the acknowledgement letter with the Master File number 29754 as a reference. This means that ArcticZymes can provide its customers with a Letter of Authorization (LoA) for their product registrations with the US FDA upon request. AZT anticipates commercial launch of SAN HQ GMP in Fourth Quarter 2023. Reported Earnings • Aug 18
Second quarter 2023 earnings released: EPS: kr0.11 (vs kr0.17 in 2Q 2022) Second quarter 2023 results: EPS: kr0.11 (down from kr0.17 in 2Q 2022). Revenue: kr28.2m (down 7.0% from 2Q 2022). Net income: kr5.60m (down 36% from 2Q 2022). Profit margin: 20% (down from 29% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Ankündigung • Jul 17
ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023 ArcticZymes Technologies ASA announced the appointment of Michael Akoh as its new Chief Executive Officer. Michael is an accomplished business executive with strong leadership experience, and an established reputation in the life sciences sector. He has over 20+ years of international experience in general management, business development and commercialization within the biopharma industry, including senior roles at diagnostic, med tech and CRO companies. Michael holds a BSc. (Econ) and a MSc. in International Marketing and Management from the Copenhagen Business School. Michael will commence his position no later than 1 November 2023. Reported Earnings • May 05
First quarter 2023 earnings released: EPS: kr0.10 (vs kr0.41 in 1Q 2022) First quarter 2023 results: EPS: kr0.10 (down from kr0.41 in 1Q 2022). Revenue: kr31.2m (down 37% from 1Q 2022). Net income: kr5.04m (down 76% from 1Q 2022). Profit margin: 16% (down from 42% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in the United Kingdom. Recent Insider Transactions • Feb 05
Director recently bought kr426k worth of stock On the 3rd of February, Jane Theaker bought around 10k shares on-market at roughly kr42.39 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr257k more in shares than they have sold in the last 12 months. Reported Earnings • Feb 04
Full year 2022 earnings released: EPS: kr0.65 (vs kr0.94 in FY 2021) Full year 2022 results: EPS: kr0.65 (down from kr0.94 in FY 2021). Revenue: kr137.7m (up 5.0% from FY 2021). Net income: kr33.1m (down 29% from FY 2021). Profit margin: 24% (down from 35% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment deteriorated over the past week After last week's 26% share price decline to kr53.00, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 27x in the Biotechs industry in Europe. Total loss to shareholders of 38% over the past year. Board Change • Nov 16
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: kr0.05 (vs kr0.14 in 3Q 2021) Third quarter 2022 results: EPS: kr0.05 (down from kr0.14 in 3Q 2021). Revenue: kr29.7m (up 12% from 3Q 2021). Net income: kr2.49m (down 64% from 3Q 2021). Profit margin: 8.4% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Reported Earnings • Aug 19
Second quarter 2022 earnings released: EPS: kr0.17 (vs kr0.09 in 2Q 2021) Second quarter 2022 results: EPS: kr0.17 (up from kr0.09 in 2Q 2021). Revenue: kr30.3m (up 35% from 2Q 2021). Net income: kr8.75m (up 86% from 2Q 2021). Profit margin: 29% (up from 21% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 10% growth forecast for the Biotechs industry in the United Kingdom. Recent Insider Transactions • Jul 06
Director recently sold kr169k worth of stock On the 4th of July, Volker Wedershoven sold around 2k shares on-market at roughly kr79.30 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr11m more than they bought in the last 12 months. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: kr0.41 (vs kr0.40 in 1Q 2021) First quarter 2022 results: EPS: kr0.41 (up from kr0.40 in 1Q 2021). Revenue: kr49.2m (up 20% from 1Q 2021). Net income: kr20.8m (up 7.5% from 1Q 2021). Profit margin: 42% (down from 47% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 23%, compared to a 12% growth forecast for the industry in the United Kingdom. Board Change • Apr 27
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Jan 28
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: kr0.92 (down from kr1.53 in FY 2020). Revenue: kr131.0m (up 34% from FY 2020). Net income: kr46.2m (down 37% from FY 2020). Profit margin: 35% (down from 75% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.8%. Over the next year, revenue is forecast to grow 20%, compared to a 15% growth forecast for the pharmaceuticals industry in the United Kingdom. Recent Insider Transactions • Dec 12
Chief Executive Officer recently sold kr11m worth of stock On the 10th of December, Jethro Holter sold around 120k shares on-market at roughly kr88.00 per share. This was the largest sale by an insider in the last 3 months. This was Jethro's only on-market trade for the last 12 months. Reported Earnings • Oct 30
Third quarter 2021 earnings released: EPS kr0.14 (vs kr0.19 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr26.4m (down 16% from 3Q 2020). Net income: kr6.89m (down 24% from 3Q 2020). Profit margin: 26% (down from 29% in 3Q 2020). The decrease in margin was driven by lower revenue. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS kr0.09 (vs kr0.44 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr22.4m (down 34% from 2Q 2020). Net income: kr4.70m (down 78% from 2Q 2020). Profit margin: 21% (down from 63% in 2Q 2020). The decrease in margin was primarily driven by higher expenses. Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment deteriorated over the past week After last week's 21% share price decline to kr81.45, the stock trades at a forward P/E ratio of 80x. Average forward P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 86% over the past year. Recent Insider Transactions • May 20
Director recently sold kr1.7m worth of stock On the 18th of May, Volker Wedershoven sold around 20k shares on-market at roughly kr85.12 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improved over the past week After last week's 17% share price gain to kr97.60, the stock trades at a trailing P/E ratio of 54.8x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 1,612% over the past three years. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS kr0.40 (vs kr0.19 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: kr41.0m (up 109% from 1Q 2020). Net income: kr19.4m (up 110% from 1Q 2020). Profit margin: 47% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has increased by 146% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jan 30
Full year 2020 earnings released: EPS kr1.75 (vs kr0.13 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr97.8m (up 16% from FY 2019). Net income: kr75.4m (up kr81.8m from FY 2019). Profit margin: 77% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 120% per year whereas the company’s share price has increased by 116% per year. Valuation Update With 7 Day Price Move • Nov 20
Market pulls back on stock over the past week After last week's 89% share price decline to kr6.60, the stock is trading at a trailing P/E ratio of 71.8x, down from the previous P/E ratio of 674.1x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Valuation Update With 7 Day Price Move • Nov 13
Market pulls back on stock over the past week After last week's 89% share price decline to kr6.60, the stock is trading at a trailing P/E ratio of 63.4x, down from the previous P/E ratio of 599.1x. This compares to an average P/E of 42x in the Biotechs industry in Europe. 
